Pérez-Becerra R, Morales-Montor JG, Santana-Ríos ZA, Hernández-Castellanos V, Saavedra-Briones D, Fulda-Graue S, Urdiales-Ortiz A, Camacho-Castro AJ, Camarena-Reynoso H, Cantellano-Orozco M, Calderón-Ferro F, Pacheco-Gahbler C

Language: Spanish
References: 14
Page: 257-262
PDF size: 358.30 Kb.

ABSTRACT

Objective: To identify whether there is an association between prostate specific antigen levels measured three months after radical prostatectomy and biochemical recurrence.
Methods: Open, comparative, retrospective, cross-sectional study was carried out. Case records of patients with prostate cancer treated with radical prostatectomy at the authors’ institution from January 1991 to May 2010 were reviewed (n = 180 case records). Patients were staged according to prostate specific antigen levels and were then registered if there was biochemical recurrence (prostate specific antigen above 0.40 ng/mL); time of recurrence was recorded. Groups were compared to identify whether there was association between prostate specific antigen levels three months after surgery and biochemical recurrence frequency. Information was registered on a data collection sheet and a database was created on Excel. Descriptive statistics were carried out using STATA statistical package. Chi square test was used to compare recurrence frequency in relation to prostate specific antigen level.
Results: Mean age of patients was sixty-four years. Initial rectal examination showed stage T1a in three patients, T1b in six patients, T1c in seventy-three patients, T2a in fifty-five patients, T2b in twenty-four patients, and T2c in nineteen patients. Mean preoperative prostate specific antigen was 13 ng/mL. Mean preoperative and postoperative Gleason score was 6. Risk classification according to D’Amico groups was as follows: seventy-five patients were in low risk group, sixty patients were in intermediate risk group, and forty-five patients were in high risk group. In regard to first postoperative prostate specific antigen value, one hundred and one patients had a value of 0-0.1 ng/mL, thirty-eight patients had a value of 0.11-0.20 ng/mL, nine patients had a value between 0.21-0.30 ng/mL, twelve patients had a value between 0.31-0.39, and twenty patients had prostate specific antigen value ≥ 0.4 ng/mL. Recurrence-free survival was 73% at nineteen years and significant P was 0.0000.
Conclusions: Values of first prostate specific antigen determination after radical surgery were useful in determining biochemical recurrence risk in relation to postoperative levels found.

REFERENCES

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.

2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8.

3. Han M, Partin W, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23.

4. Pund C, Partin W, Eisenberger M, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.

5. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358-68.

6. Scher HI, Eisenberger M, D´Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004;22:537-56.

7. Stephenson A, Kattan M, Eastham J. Defining biochemical recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for Standardized Definition. J Clin Oncol 2006;24:3973-8.

8. Cookson M, Aus G, Burnett L. Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes. J Urol 2007;177:540-5.

9. Eisenberg M, Davies B, Cooperberg M. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;58:e33.

10. Amling CL, Bergstralh EJ, Blute ML, et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001;165:1146-51.

11. William A See. PSA changes in early prostate cancer: Implications for patient management. European Urology Supplements 2002;1:17-23.

12. Lughezzani G, Budäus L, Isbarn H, et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol 2010;57:562-8.

13. Simmons M, Stephenson A, Klein E. Natural history of biochemical recurrence after radical prostatectomy: Risk assessment for secondary therapy. Eur Urol 2007;51:1175-84.

14. Jhaveri F, Zippe C, Klein E, Kupelian P. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 1999;54:884-90.